AU664212B2 - Quinoxaline derivates with affinity for quisqualate-receptors - Google Patents

Quinoxaline derivates with affinity for quisqualate-receptors

Info

Publication number
AU664212B2
AU664212B2 AU28894/92A AU2889492A AU664212B2 AU 664212 B2 AU664212 B2 AU 664212B2 AU 28894/92 A AU28894/92 A AU 28894/92A AU 2889492 A AU2889492 A AU 2889492A AU 664212 B2 AU664212 B2 AU 664212B2
Authority
AU
Australia
Prior art keywords
quisqualate
receptors
affinity
derivates
quinoxaline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU28894/92A
Other languages
English (en)
Other versions
AU2889492A (en
Inventor
Ilse Beetz
Peter Holscher
Andreas Huth
Martin Kruger
Peter Andreas Loschmann
Dieter Rahtz
Ralph Schmiechen
Ingrid Schumann
Dieter Seidelmann
David Norman Stephens
Lechoslaw Turski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4135871A external-priority patent/DE4135871A1/de
Application filed by Schering AG filed Critical Schering AG
Publication of AU2889492A publication Critical patent/AU2889492A/en
Application granted granted Critical
Publication of AU664212B2 publication Critical patent/AU664212B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU28894/92A 1991-10-26 1992-10-25 Quinoxaline derivates with affinity for quisqualate-receptors Ceased AU664212B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4135871A DE4135871A1 (de) 1991-10-26 1991-10-26 Chinoxalinderivate, deren herstellung und verwendung in arzneimitteln
DE4135871 1991-10-26
DE4224200 1992-07-17
DE4224200 1992-07-17
PCT/DE1992/000895 WO1993008173A1 (fr) 1991-10-26 1992-10-25 Derives de quinoxaline ayant une affinite pour les recepteurs de quisqualate

Publications (2)

Publication Number Publication Date
AU2889492A AU2889492A (en) 1993-05-21
AU664212B2 true AU664212B2 (en) 1995-11-09

Family

ID=25908683

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28894/92A Ceased AU664212B2 (en) 1991-10-26 1992-10-25 Quinoxaline derivates with affinity for quisqualate-receptors

Country Status (17)

Country Link
EP (1) EP0565683A1 (fr)
JP (1) JP3258008B2 (fr)
KR (1) KR100262371B1 (fr)
CN (1) CN1038840C (fr)
AU (1) AU664212B2 (fr)
CA (1) CA2099270A1 (fr)
CZ (1) CZ286351B6 (fr)
FI (1) FI932959A0 (fr)
HU (1) HUT64756A (fr)
IL (1) IL103538A (fr)
NO (1) NO304693B1 (fr)
NZ (1) NZ244896A (fr)
PL (1) PL171125B1 (fr)
PT (1) PT101004B (fr)
RU (1) RU2117663C1 (fr)
SK (1) SK281518B6 (fr)
WO (1) WO1993008173A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
AU672617B2 (en) * 1992-06-22 1996-10-10 Regents Of The University Of California, The Glycine receptor antagonists and the use thereof
DE4314592A1 (de) * 1993-04-28 1994-11-03 Schering Ag Benzo(f)chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
DE4428152A1 (de) * 1994-06-22 1996-01-04 Basf Ag Neue Amido-chinoxalindione, ihrer Herstellung und Verwendung
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
US6096743A (en) * 1994-09-27 2000-08-01 Yamanouchi Pharmaceuticals Co., Ltd. 1,2,3,4-tetrahydroquinoxalinedione derivative
DE4439493A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
DE19521058A1 (de) * 1995-06-09 1996-12-12 Basf Ag Verfahren zur Herstellung von Aromaten enthaltenden Polyetherpolyolen
DE19545251A1 (de) * 1995-11-24 1997-05-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
DE19624808A1 (de) 1996-06-21 1998-01-02 Basf Ag Pyrrolylchinoxalindione, ihre Herstellung und Verwendung
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
EP0900567A3 (fr) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
FR2769309B1 (fr) 1997-10-08 2001-06-15 Oreal Composition de teinture d'oxydation des fibres keratiniques comprenant un derive d'aminoacide en tant que base d'oxydation et nouveaux derives d'aminoacides
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7576791A (en) * 1990-03-16 1991-10-10 Novo Nordisk A/S Quinoxaline compounds and their preparation and use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118982A1 (fr) * 1983-02-01 1984-09-19 Sumitomo Chemical Company, Limited Composés organo-phosphorés de la quinoxalinone, leur production et utilisation
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7576791A (en) * 1990-03-16 1991-10-10 Novo Nordisk A/S Quinoxaline compounds and their preparation and use

Also Published As

Publication number Publication date
NO932344D0 (no) 1993-06-25
FI932959A (fi) 1993-06-24
NZ244896A (en) 1995-07-26
NO932344L (no) 1993-06-25
HU9301877D0 (en) 1993-09-28
PT101004A (pt) 1994-01-31
IL103538A (en) 2001-07-24
PT101004B (pt) 1999-10-29
RU2117663C1 (ru) 1998-08-20
IL103538A0 (en) 1993-03-15
PL171125B1 (pl) 1997-03-28
JP3258008B2 (ja) 2002-02-18
FI932959A0 (fi) 1993-06-24
KR100262371B1 (ko) 2000-08-01
CZ286351B6 (cs) 2000-03-15
KR930703271A (ko) 1993-11-29
AU2889492A (en) 1993-05-21
WO1993008173A1 (fr) 1993-04-29
CN1038840C (zh) 1998-06-24
NO304693B1 (no) 1999-02-01
CZ138793A3 (en) 1994-01-19
JPH06503583A (ja) 1994-04-21
SK281518B6 (sk) 2001-04-09
EP0565683A1 (fr) 1993-10-20
CA2099270A1 (fr) 1993-04-27
HUT64756A (en) 1994-02-28
CN1072929A (zh) 1993-06-09
PL299929A1 (en) 1994-04-05
SK72793A3 (en) 1993-10-06

Similar Documents

Publication Publication Date Title
AU664212B2 (en) Quinoxaline derivates with affinity for quisqualate-receptors
AU2248992A (en) Connector block assembly
AU2454992A (en) Dispersions
AU2447492A (en) User-propelled vehicle
AU1823492A (en) Imidazodiazepines
AU1062792A (en) Turntable
AU2121092A (en) Benzodioxanderivate
AU1930992A (en) Pyrrolopyrazines
AU1782292A (en) Gridbeam
AU1556892A (en) 2-substituted-2-imidazolines
AU1908892A (en) Assembly apparatus
AU4760193A (en) Antioxidant
AU1080292A (en) Ige-receptor-antibodies
AU1432092A (en) Quinoxaline phosphono-amino acids
AU657142B2 (en) Dithianes
AU3712589A (en) Polyethyleneimine matrixes for affinity chromatography
AU1752492A (en) Diamino-alpha-alkylstilbenes
AU1732692A (en) Substituted imidazolinylpyrimidines
AU2040192A (en) Quinolin-2-yl-methoxybenzylhydroxyureas
AU7138791A (en) Skip
AU1588892A (en) Watch-strap
AU1624092A (en) Mopheads
AU1669792A (en) Azabicycloheptanone
AU3033592A (en) Shuttlecar equaliser
AU1581092A (en) Nystagmograph

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired